GlassScriptPhysician profile
Lisa M Stenvers
NPI 1841265097
$4,399.45
in general payments reported to CMS, 2019-2025
41 companies · $1,318 in 2025
The $1,318 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $470 · 2022: $780 · 2023: $1,012 · 2024: $819 · 2025: $1,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,148.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,264.85 | 2021-2025 | |
| Amgen INC. | $550.93 | 2021-2025 | Evenity, Prolia, Repatha |
| Otsuka America Pharmaceutical, INC. | $385.61 | 2022-2025 | Rexulti |
| Pfizer INC. | $324.95 | 2021-2025 | |
| Novo Nordisk INC | $302.97 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $256.17 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $188.21 | 2022-2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.70 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $87.39 | 2021-2025 | |
| Mannkind Corporation | $71.02 | 2023-2025 | Afrezza |
| Vanda Pharmaceuticals INC. | $61.55 | 2024-2025 | Fanapt, Hetlioz |
| Abbott Laboratories | $57.91 | 2022-2023 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.46 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.58 | 2021-2025 | Xifaxan |
| Lundbeck LLC | $49.15 | 2024-2025 | Rexulti |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Stenvers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.